Skip to content

Clinical application of 3D bioprinted organoid drug screen in adjuvant chemotherapy of pancreatic cancer

Clinical application of 3D bioprinted organoid drug screen in adjuvant chemotherapy of pancreatic cancer

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200066886
Enrollment
Unknown
Registered
2022-12-20
Start date
2023-01-01
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic cancer

Interventions

Experimental group:?Patients receive relatively sensitive chemotherapy regimen based on the results of organoid drug screening
Control group:Chemotherapy regimens will be formulated by oncologists or pancreatic surgeons according to guidelines for pancreatic cancer and the patient's condition.

Sponsors

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Patients have good compliance, can understand the study process, and signed the written informed consent; (2) age =18 years old and =70 years old; (3) patients with a histopathological or cytological diagnosis of pancreatic ductal adenocarcinoma, or a clinical diagnosis of pancreatic ductal adenocarcinoma Of the patients; (4) ECOG=1; (5) predicted survival time=3 months; (6) expected radical resection of the tumor; (7) no distant metastasis; (8) no history of neoadjuvant chemoradiotherapy; (9) There were no serious systemic complications.

Exclusion criteria

Exclusion criteria: (1) patients with other malignant tumors or received antitumor therapy in the past 5 years; (2) non-pancreatic ductal adenocarcinoma confirmed by postoperative pathology; (3) patients unable to receive chemotherapy due to postoperative complications or poor physical status; (4) patients of childbearing age who are pregnant or lactating or who refuse to use appropriate contraception during the course of the trial; (5) having participated in other trial investigators within 30 days; (6) patients with failure of organoid model construction or failure of drug screening experiments due to various reasons; (7)Patients who were deemed by the investigator to be ineligible for the trial.

Design outcomes

Primary

MeasureTime frame
One-year survival rate;

Secondary

MeasureTime frame
Disease-free survival;Overall survival;

Countries

China

Contacts

Public ContactZhang Taiping

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

doc.gang@qq.com13520132976

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026